



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 33/14, 9/52		A1	(11) International Publication Number: WO 86/ 04817 (43) International Publication Date: 28 August 1986 (28.08.86)
 (21) International Application Number: PCT/US86/00318			(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).
 (22) International Filing Date: 19 February 1986 (19.02.86)			
 (31) Priority Application Number: 702,714			
 (32) Priority Date: 19 February 1985 (19.02.85)			
 (33) Priority Country: US			
 (71) Applicant: KEY PHARMACEUTICALS, INC. [US/US]; 4400 Biscayne Boulevard, Miami, FL 33137 (US).			
 (72) Inventors: HSIAO, Charles ; CHOU, Chi-Tze, Ku ; 4400 Biscayne Boulevard, Miami, FL 33137 (US).			
 (74) Agents: WEGNER, Harold, C. et al.; Wegner & Bretschneider, P.O. Box 18218, Washington, DC 20036 (US).			

(54) Title: CONTROLLED RELEASE POTASSIUM CHLORIDE

(57) Abstract

A controlled release potassium chloride tablet which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro pellets which then can be compressed into tablets. The tablets disintegrate rapidly in an aqueous environment thus assuring a more uniform dissolution of the active component as compared with other types of controlled release potassium chloride dosage formulations. The distribution of the potassium chloride micro pellets over a wide surface area in the gastrointestinal mucosa aids in reducing the risk of gastrointestinal lesions. The formation of the coated micro pellets which disperse quickly upon contact with aqueous environment allow for the repeated chronic oral administration of a relatively large dose of potassium chloride (20 mEq).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	GA Gabon	MR Mauritania
AU Australia	GB United Kingdom	MW Malawi
BB Barbados	HU Hungary	NL Netherlands
BE Belgium	IT Italy	NO Norway
BG Bulgaria	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroon	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland	ML Mali	
FR France		

CONTROLLED RELEASE POTASSIUM CHLORIDEFIELD OF THE INVENTION

The present invention relates to a controlled release potassium chloride tablet. More specifically, the present invention relates to a controlled release potassium chloride tablet comprised of polymer coated crystals of KCl which is orally administered to a patient requiring potassium supplementation which tablet provides for controlled release of the potassium chloride in the gastrointestinal tract and results in substantially less irritation to the gastric mucosa.

BACKGROUND OF THE INVENTION

It is well known that the administration of many diuretics increases the excretion of both sodium and potassium. The acute administration of such diuretics to a patient normally causes no problems. However, chronic administration of diuretics to the patient can result in the depletion of the potassium from the patient. For example, with patients having uncomplicated hypertension, the daily administration of diuretics produces a slight reduction in plasma potassium concentration. In edematous patients, the results are more variable. Some patients suffer from substantial depletion of potassium while others fail to show any evidence of depletion. There is a high incidence of severe potassium deficiency in patients treated simultaneously with diuretics and carbenoxolone which is an agent with mineralocorticoid activity.

As can be seen from the above discussion various treatments can result in potassium depletion, i.e., hypokalemia. Potassium depletion may be accompanied by a reduced tolerance to carbohydrates and a deficiency in glycogen deposition. Further, vasopressin-resistant polyuria is a prominent symptom. A deficit of potassium appears to increase the renal synthesis of prostaglandins, which in turn can decrease the

-2-

permeability to water of the distal nephron and produce a diabetes insipidus-like syndrome.

When potassium is taken along with a normal diet it is slowly absorbed from the intestinal tract. Following distribution and uptake by the cells the kidneys excrete an appropriate amount to maintain a proper balance. As a consequence of the large volume of distribution and the rapid response of the kidney, the extracellular and intracellular concentrations of the ion are normally maintained within relatively narrow limits.

When potassium is administrated as a drug, the factors that can govern the rate and extent of its distribution are of major importance. It is not possible to increase the total body content of potassium significantly above normal. However, it is very easy to raise the extracellular concentration excessively. It is the concentration in the extracellular fluid that determines life-threatening toxicity. Therefore, even though the administered potassium is eventually destined either to be excreted or taken up by the cells, knowledge of the transient concentration achieved in the plasma must govern the use of potassium as a therapeutic agent.

It is well known that large doses of potassium chloride taken orally can cause GI irritation, purging, weakness and circulatory disturbances. Since potassium depletion can cause problems for the patient as indicated above a controlled release formulation of potassium chloride which would replenish potassium in a controlled manner without the undesirable side effects is badly needed. In an attempt to meet the need of providing dosage units which can be used as potassium supplements a number of different dosage forms have been developed. For example U.S. Patent 4,352,791 discloses a composition comprised of potassium and a therapeutically acceptable salicylate salt of salicylic acid. The composition is used in potassium therapy and

-3-

is useful in some respects but does not provide sufficient protection with respect to preventing gastric ulcers.

U.S. Patent 4,340,582 discloses an enteric coated erythromycin tablet and a water-soluble nontoxic salt in the core. This core may be potassium chloride.

U.S. Patent 4,259,323 discloses a potassium chloride emulsion which includes various ingredients in an attempt to mask the bad taste of the potassium chloride. However, dosing compliance utilizing an emulsion often causes problems in that the emulsion may settle and the patient may take different amounts of the emulsion and/or different amounts of the KCl in a given amount of emulsion.

U.S. Patent 4,259,315 discloses a controlled release potassium dosage form used in treating potassium deficiency. The dosage form is comprised of gelatin capsules which contain a mixture comprised of controlled release forms of micro encapsulated potassium salt and a hydrophilic surfactant.

Sugar-coated tablets containing potassium chloride in a wax matrix (non-enteric-coated) are marketed as a slowly available potassium source. Physicians Desk Reference (1979), page 794, states "fewer bowel lesions are observed with wax-matrix tablets compared to enteric-coated potassium chloride products, but that there have been reports of upper gastrointestinal bleeding associated with the wax-matrix tablets. Use of these wax-coated products should be discontinued immediately and the possibility of bowel obstruction or perforation considered if severe vomiting, abdominal pain, distention or gastrointestinal bleeding occurs." (See USP 4,259,315).

A slow release pharmaceutical composition is disclosed within U.S. Patent 4,235,870. The composition is comprised of a combination of higher aliphatic alcohols and hydrated hydroxy-alkyl cellulose in a ratio

-4-

of 2:1 to 4:1 parts by weight. The composition is intended to provide slow release of the therapeutically active compound during a predetermined period of time of from 5 to 10 hours after oral administration of the composition. However, this composition tends to remain intact and does not disintegrate, thus producing high concentrations of KCl.

Others have used surfactants to improve dissolution rate of drugs when powders agglomerate and teach the rate of dissolution is proportional to the reduction in surface tension of the gastric juice (Remington's Pharmaceutical Sciences, 15th Ed. (1973) p. 297). Others have used surfactants such as Polysorbate 20 as an ingredient interior to microcapsules during preparation of microcapsules and have discussed the adverse effect of such agents on the increased release rate of solids from the microcapsules (Luzzi et al. J. Pharm. Sci. 56(9), 1174-7 (1967). (See USP 4,259,315).

The present inventors have found that the potassium chloride dosage forms presently available are not meeting all the needs of patients requiring potassium supplementation. Accordingly, the following invention was developed.

SUMMARY OF THE INVENTION

The present invention is a controlled release potassium chloride tablet. More specifically, the invention relates to a tablet which includes potassium chloride crystals which are coated with about 9.5 to 18% by weight of a polymeric mixture. The crystals preferably have a mesh size in the range of about 30 to 50 mesh and the coating is preferably comprised of from about 9.0 to about 15 parts by weight of ethylcellulose and about 0.5 to about 3.0 parts by weight hydroxypropylcellulose. The tablets also may include a compression aid; a disintegrant and a tableting lubricant.

-5-

A primary object of the present invention is to provide a controlled release potassium chloride tablet capable of being orally administered and safely replenishing potassium in a patient suffering from potassium depletion.

Another object of the present invention is to provide such a controlled release potassium chloride tablet which when administered orally minimizes adverse side effects such as GI irritation, purging, weakness and circulatory disturbances.

Still another object of the present invention is to provide such a controlled release potassium chloride tablet which acts as a safe electrolyte replenisher.

Another object of the present invention is to provide a safe method of treating patients suffering from potassium depletion.

Yet another object of the present invention is to provide a controlled release potassium chloride tablet which can be co-administered with a diuretic to a patient in a manner so as to prevent potassium depletion from the patient.

These and other objects of the invention will become apparent to those skilled in the art upon reading this disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The essence of the present invention is a controlled release potassium chloride tablet. The active ingredient of the tablet is the salt potassium chloride and specifically the cation potassium. The potassium cation is preferably administered to the patient in such a manner so as to avoid side effects and

-6-

prevent or relieve potassium depletion. The KCl tablets of the present invention may be co-administered with a diuretic.

The salt potassium chloride (KCl) occurs in nature as the mineral sylvine or sylvite. Various industrial preparations of potassium chloride exist. Further, there are numerous pharmaceutical potassium chloride preparations. The salt potassium chloride is a white crystal or crystalline powder having the following physical description: d 1.98. mp 773°C; 1 gram dissolves in 2.8 ml water; 1.8 ml boiling water; 14 ml glycerol; about 250ml alcohol; insoluble ether and acetone.

In accordance with the present invention potassium chloride crystals having a particle size distribution ranging from about 30 to about 50 mesh (about 0.59-0.29 mm), preferably about 40 mesh (about 0.37 mm), are utilized as "seed" crystals subjected to coating or microencapsulation and subsequently compressed into the tablet. In accordance with the present invention only minor amounts of the crystals would fall outside of the range disclosed above.

When the potassium chloride crystals having the size disclosed above are obtained they are then coated with a polymeric coating which includes ethylcellulose as a major component and hydroxypropylcellulose as a minor component. The weight ratio of the ethylcellulose to the hydroxypropylcellulose is at least 3.0. In accordance with the present invention it is contemplated that the weight ratio (ethylcellulose : hydroxypropylcellulose) can range from about 3.0:1 to about 30:1 with a preferred range being from about 5.0:1 to about 18:1, and still more preferably about 9:1. Hydroxypropylcellulose (molecular weight 60,000-1,000,000 preferably about 100,000) is sold under the trademark Klucel® by Hercules. The hydroxypropyl cellulose may be replaced in whole or in part with polyethylene glycol, such as that sold under the

-7-

trademark Carbowax ® by Union Carbide. Molecular weights of 200-8000 are useful, with 1000-6000 being preferred.

By providing the proper balance of the ethylcellulose to the hydroxypropylcellulose a polymer film can be formed on the seeds which will remain intact in the stomach (and afterwards) but which is permeable to gastric fluids, which dissolve and leach out the potassium chloride contained in the coated crystals (micro pellets). Further, these micro pellets will separate quickly upon reaching the stomach and thus avoid the accumulation of any large amount of KCl which could cause irritation.

The polymeric coating (combination of ethylcellulose and hydroxypropylcellulose) on the crystals makes up about 9.5 to about 18% of the total weight of the micro pellets and preferably about 13.3% of the weight of the micro pellets. Lesser amounts, that is, amounts below about 9% of the total weight of the micro pellets can cause the formation of bare spots on the potassium chloride crystals during the compression step, leading to undesirably rapid release of the potassium chloride in the body after oral administration. Increasing the amount of polymeric coating substantially above 18% can cause the potassium chloride to be released too slowly to be completely absorbed by the patient.

-8-

The present inventors have found it preferable to use a coating comprising ethylcellulose in an amount of about 9.0 to 15% by weight based on the total weight of the micro pellets, more preferably 11.9% by weight, and hydroxypropylcellulose in an amount of about 0.5 to 3.0%.

It is particularly preferred to use a higher molecular weight ethyl cellulose such as that designated as 100 and sold under the trademark Ethocel® Standard Premium 100 or Ethocel® Medium 100 by Dow Chemical. The use of higher molecular weight material like the 100 designation material limits breakage during compression. The numerical designations for ethylcellulose generally correspond to the viscosity of the product, with a higher numerical designation indicating a greater viscosity and higher molecular weight. The 100 designation corresponds to a viscosity of about 85-110 cp as measured in a 5% solution in an 80% toluene-20% ethanol solvent. The useful ethylcellulose designations are 7 and higher, corresponding to a viscosity of at least 6 cp, preferably more than 40 cp (designation 45 or higher) for crystals to be compressed into tablets. The ethoxyl content can be about 45-49.5%, preferably 45-46.5%. The present inventors determined that ethylcellulose 100 was preferred as compared with other ethylcellulose products as there is less breakage during compression. The lower viscosity ethylcelluloses, such as the type 10, are especially useful in making coated crystals for administration in capsules, when breakage from compression is not a problem.

-9-

Potassium chloride is normally provided in relatively large oral dosages in the range of 2 to 4 grams daily. Because of the large amount of the salt which is provided to the patient gastrointestinal irritation is common. This irritation can range from a slight discomfort to gastric ulcers. By including the crystals in the micro pellets in the manner indicated above and then compressing them in a conventional manner into tablets, the gastrointestinal irritation is alleviated or eliminated.

The individual crystals of potassium chloride having the mesh sizes indicated above are coated with the appropriate sustained release agents and compressed into tablets in a conventional manner. The tablets are coated and compressed in a manner so as to allow the tablets to disintegrate relatively quickly upon contact with an aqueous environment into the individual coated crystals, i.e., disintegration takes place in less than five minutes after oral administration.

The manufacturing process utilized applies a controlled and uniform coating permitting a more uniform dissolution as compared to a wax matrix and/or a coacervation formulation. Accordingly, the rapid disintegration and controlled dissolution of the tablets produced according the present invention permit the peristaltic motion of the gut to distribute the coated crystals over a wide surface area. Accordingly, concentrated quantities of potassium chloride do not come in contact with the GI mucosa, thus reducing the chances for gastric ulcers. This is one of the most important features of the present invention.

-10-

The importance of potassium supplement therapy has been well established. Physicians need products for the prevention of hypokalemia during chronic diuretic therapy. Compliance is essential for patients undergoing this type of therapy. The recommended dose in most patients is 40 mEq per day in divided doses. In accordance with currently approved labeling 20 mEq, or 2 doses having a size of 10 mEq should be taken twice daily in order to obtain a daily dose of 40 mEq. With the formulation provided by the present invention the tablet will include 20 mEq so that the recommended effective amount of potassium per single dose would not be altered. The daily dose would be achieved with one tablet twice daily thus facilitating compliance due to less individual units per dose. A 20 mEq tablet also presents to the physician a more palatable dosage form to the 20 mEq liquid therapy and an alternative to prescribing two tablets of the same sustained release formulation.

In severe cases of hypokalemia, higher doses (60-80 mEq) of potassium are required to reduce the loss of potassium during high dose diuretic therapy. In such cases, the physician would have available a safe higher strength tablet where, in his judgement, he is treating a patient with a compliance problem. Evidence exists that the tablet produced according to the present invention is non-irritating and non-toxic to the gastrointestinal tract.

The tablets produced in accordance with the present invention disintegrate into numerous sub-units when placed in water or placed on an aqueous food. After being disintegrated into the sub-units or micro pellets the potassium chloride of the present invention can be

-11-

more easily administered to children and geriatric patients who often have difficultly in swallowing large tablets. The tablets can include conventional compression aids, e.g. microcrystalline cellulose, disintegrants, e.g. crospovidone, and lubricating agents, e.g. magnesium stearate.

Examples are prepared as indicated below:

EXAMPLE 1

The potassium chloride crystals (30-50 mesh) were coated in a 6" Wurster fluidized bed column with 15% (w/w) of Ethocel® 10 and PEG 4500 E. (14:1 ratio). The Ethocel® type 10 and PEG 4500 E were dissolved in chloroform and methanol co-solvent system (4:1 ratio). The crystals were coated at 60°C inlet temperature. The spraying pressure was 1.5 bars and the spray speed was approximately 15ml per minute. Afterwards, 93% of the coated crystals, 6% of Avicel® PH101 (microcrystalline cellulose) and 1% of crospovidone (cross-linked polyvinylpyrrolidone) were mixed well and compressed into tablets with a Stokes DS 3 press, equipped with capsule-shape punches (0.34" x 0.873" x 0.086"). The dosage of the tablets was 20 mEq or 1500 mg KCl.

-12-

A second batch of potassium chloride crystals was coated with 15% (w/w) of Ethocel® type 100 and PEG 4500 E (14:1 ratio) and compressed into tablets which included the excipients indicated above. All the experimental procedures were the same as mentioned above, except the type of ethylcellulose used.

A dissolution study of the coated crystals (micro pellets) was performed in deionized water.

The following table is a summary of the dissolution test:

TABLE I
CUMULATIVE % KCl RELEASED

	1hr	2hr	4hr	6hr	Ethylcellulose Type
Coated Crystals	17	35	63	85	Ethocel® 10
Tablets	46	63	83	96	
Coated Crystals	12	59	86	96	<u>Ethocel® 100</u>
Tablets	15	40	76	91	

EXAMPLE 2

The potassium chloride crystals (30-50 mesh size) were coated in a 6" Wurster fluidized bed column with 15% (w/w) of Ethocel® 10, Klucel® L.F. and Mg stearate (8.5:1:0.5 ratio). The Ethocel® 10 and Klucel® L.F. were dissolved in a chloroform and

-13-

methanol co-solvent system. Magnesium stearate was then added to the polymer solution to form a suspension. The suspension was stirred by a lab stirrer throughout the coating process to avoid the sedimentation of magnesium stearate. The crystals were coated at 60°C inlet temperature. The spraying pressure was 1.5 bars and the spray speed is approximately 15 ml per minute. Afterwards, 93% of the coated crystals, 6% of Avicel® PH101 (microcrystalline cellulose) and 1% of crospovidone (cross-linked polyvinylpyrrolidone) are mixed well and compressed into capsule-shaped tablets. The dosage of the tablets was 20 mEq or 15mg of KCl.

A second batch of potassium chloride crystals was coated with 15% (w/w) of Ethocel® 100, Klucel® L.F. and magnesium stearate (8.5:1:0.5 ratio) and compressed into tablets with the same excipients indicated above. All the experimental procedures were the same as mentioned above except the type of ethylcellulose used.

A dissolution study of the coated crystals and tablets was performed in deionized water.

-14-

The following table is a summary of the dissolution test:

TABLE II
CUMULATIVE % KCl RELEASED

	1hr	2hr	4hr	6hr	Ethocel Type
Coated Crystals	33	52	78	94	Ethocel® 10
Tablets	52	69	86	97	
Coated Crystals	27	59	84	95	Ethocel® 100
Tablets	26	55	83	94	

In accordance with a preferred embodiment of the present invention potassium chloride tablets containing 1500mg of potassium chloride are prepared. The potassium crystals form about 68% to about 86.5% by weight of these tablets and are coated with ethylcellulose (preferably Ethocel® 100) in an amount in the range of 9 to 15% by weight based on the weight of the micro pellets formed with the potassium chloride crystals; 0.5 to 3% by weight of hydroxypropylcellulose based on the weight of the micro pellets; 0.5 to 2% by weight of magnesium stearate based upon the weight of the tablet; 3 to 10% by weight of microcrystalline cellulose based upon the weight of the tablet; 0.5 to 2% by weight crospovidone based upon the weight of the tablet.

-15-

Within each of these ranges it is particularly preferred for the 1500mg tablets to include 79 weight percent of potassium chloride, 11.9% by weight of ethylcellulose (preferably Ethocel® 100), 1.4% by weight hydroxypropylcellulose, 0.7% by weight of magnesium stearate, 6% by weight of microcrystalline cellulose and 1% by weight of crospovidone.

In accordance with the present invention a clinical batch of 1500mg tablets of potassium chloride were prepared. The tablets were comprised as shown in the following Table III.

-16-

TABLE III

POTASSIUM CHLORIDE S.R. TABLETS

20 mEq

QUANTITATIVE LIST OF COMPONENTS

QUANTITY/ TABLETS	INGREDIENTS	QUANTITY/ BATCH	% WT.
(20 mEq) 1500mg	Potassium Chloride, USP	255.00kg	79.0
225mg	Ethylcellulose, NF (Ethocel®, Type 100)	38.25kg	11.9
27mg	Hydroxypropylcellulose, NF (Klucel®, L.F.)	4.50kg	1.4
13mg	Magnesium Stearate, NF	2.25kg	0.7
114mg	Microcrystalline Cellulose, NF (Avicel® PH 101)	19.36kg	6.0
19mg	Crospovidone, NF (Polypetasone XL)	3.23kg	1.0
*	Methyl Alcohol, NF (Methanol)	168.65kg	*
*	Methylene Chloride, NF	846.45kg	*
1898mg	TOTALS	322.59kg/ 170,000 Tablets	

* Removed during processing.

COMPARATIVE EXPERIMENT

In order to demonstrate the safety of the present invention, a clinical study was carried out which compared potassium chloride tablets (20 mEq) produced in accordance with the present invention with four commercial products as follows: Slow-K (a

-17-

sugar-coated wax matrix tablet from Ciba); Micro-K Extencaps®, (capsules of crystalline KCl particles coated with polymer from A.H. Robins); Kaon® Elixir (liquid potassium gluconate), and placebo.

In this particular investigator blinded study comparing the 20 mEq KCl tablets to 4 standard preparations in a dose of 80 mEq per day, no serious endoscopic lesions were found with the tablet of the present invention. Overall, the safety of the tablet was equal to or better than any of the comparative agents.

The present invention has been disclosed and described herein in what is considered to be its most preferred embodiments. It should be noted that variations may occur to those skilled in the art upon reading the present disclosure and that such variations are intended to come within the scope of the present invention.

WHAT IS CLAIMED IS:

1. A dosage unit for oral administration of potassium chloride, comprising;

a plurality of coated potassium chloride crystals, the amount of potassium chloride being in the range of about 68% to about 86.5% by weight based on the total weight of the dosage unit;

a coating material for the individual potassium chloride crystals, the coating material comprising ethylcellulose in an amount in the range of about 9% to about 15% by weight based on the total weight of the coated crystals and at least one member selected from hydroxypropylcellulose and polyethylene glycol in an amount in the range of about 0.5% to about 3% by weight based on the total weight of the coated crystals.

2. A pharmaceutical dosage unit as claimed in claim 1, wherein the coated crystals are compressed to form a tablet.

3. A pharmaceutical dosage unit as claimed in claim 2, wherein the tablet is further comprised of magnesium stearate in an amount in the range of about 0.5% to 2.0% by weight based on the total weight of the tablet.

4. A pharmaceutical dosage unit as claimed in claim 3, wherein the tablet is further comprised of a microcrystalline cellulose in an amount in the range of about 3 to 10% by weight based on the total weight of the tablet.

5. A pharmaceutical dosage unit as claimed in claim 4, further comprising crospovidone in an amount in the range of about 0.5 to

about 2.0% by weight based on the total weight of the tablet.

6. A pharmaceutical dosage unit as claimed in claim 1, wherein the potassium chloride is in the form of crystals which have a mesh size in the range of about 30 to about 50 mesh.

7. A pharmaceutical dosage unit as claimed in claim 6, wherein the potassium chloride crystals have a mesh size of about 40 mesh.

8. A pharmaceutical dosage unit as claimed in claim 2, wherein the ethylcellulose is ethylcellulose 45 or higher.

9. A pharmaceutical dosage unit as claimed in claim 8, wherein the ethylcellulose is ethylcellulose 100.

10. A pharmaceutical dosage unit as claimed in claim 1, wherein the member selected from hydroxypropylcellulose and polyethylene glycol is hydroxypropylcellulose.

11. A pharmaceutical unit as claimed in claim 1, wherein the member selected from hydroxypropylcellulose and polyethylene glycol is polyethylene glycol.

12. A method of providing potassium to a subject in need of potassium, comprising administering to the subject a therapeutically useful amount of potassium chloride in a dosage unit according to claim 1.

13. The method of claim 12, wherein the dosage unit is disintegrated in water or on an aqueous food prior to administration.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 86/00318

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁴: A 61 K 33/14; A 61 K 9/52

II. FIELDS SEARCHED

Minimum Documentation Searched †	
Classification System	Classification Symbols
IPC ⁴	A 61 K
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *	

III. DOCUMENTS CONSIDERED TO BE RELEVANT*

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	EP, A, 0052076 (CIBA GEIGY) 19 May 1982, see pages 6-9; examples 1,2; claims 1-10 --	1-11
Y	WO, A, 84/00004 (KEY PHARMACEUTICALS) 5 January 1984, see the whole document --	1-10
Y	Chemical Abstracts, volume 94, no. 8, February 1981, Columbus, Ohio, (US) B. Lippold et al.: "Control of drug liberation from microcapsules. part 1. Legal modification for drug transport through additive-containing lipophilic membranes"; see page 362, abstract no. 52812b & Pharm. Ind. 1980, 42(7), 745-52 -----	11

- * Special categories of cited documents: ¹⁰
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

16th May 1986

Date of Mailing of this International Search Report

19 JUN 1986

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

L. ROSSI

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

..... 12,13. See PCT Rule 39.1(iv) Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods

2. Claim numbers, because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- The additional search fees were accompanied by applicant's protest.
 No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON

INTERNATIONAL APPLICATION NO. PCT/US 86/00318 (SA 12270)

This Annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 02/06/86

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0052076	19/05/82	GB-A, B JP-A- 57109715 AU-A- 7738281 CA-A- 1178202	2086725 08/07/82 20/05/82 20/11/84
WO-A- 8400004	05/01/84	EP-A- US-A-	0111560 4508702
			27/06/84 02/04/85
